← All forecasts · October 19

TMO / Q3 2026

Thermo Fisher Scientific

Reported: October 21, 2026

Published forecast

2026-10-20T08:26:00.308802+00:00

Opus 5.5 High in Shortcut

Shortcut

6.44

Shortcut normalized EPS

+0.6% vs Street

Off by $0.24 per share

Street

6.40

Street normalized EPS

Frozen October 18 snapshot

Off by $0.28 per share

Real

6.68

Issuer adjusted diluted EPS

Shortcut win

Reported result · October 21 ↗ · Issuer adjusted diluted EPS of $6.68 for the quarter ended September 26, 2026; GAAP diluted EPS was $4.64.

USD per diluted common share. Percentages use unrounded forecasts.

Model download

Explore the assumptions and calculations behind the forecast.

Open in Shortcut ↗Download XLSX ↓

Shortcut’s reasoning.

The segment build forecasts $11.97bn revenue and $2.385bn adjusted net income. Segment margins, financing, an 11.5% adjusted tax rate and 370.547m diluted shares produce EPS of $6.44 versus the Street estimate of $6.40.

Segment income and margins drive earnings; detailed expense allocations are illustrative. The normalized bridge excludes the estimated Microbiology divestiture gain, whose actual GAAP treatment remains uncertain.

Cash-flow classifications and asset allocations remain simplified. These additional metrics are tracked, not scored. The original EPS assumptions were preserved through both repair rounds.

On the record.

Reporting basis
issuer adjusted diluted EPS / CapIQ normalized EPS
Forecast completed
2026-10-19T21:17:43.220051+00:00
Published
2026-10-20T08:26:00.308802+00:00
Model assumptions and review notes
  • Segment expense detail mixes recast and originally filed historical bases. Expense ratios are illustrative; segment income and margins drive the EPS forecast. Some FY memo labels describe sums rather than independent reported inputs.
  • The approximately $203m Microbiology divestiture gain, its tax effect and asset allocation are estimates used only in the GAAP memo; the normalized forecast excludes the gain.
  • Cash-flow details use simplified asset/channel allocations and an unresolved CCIRS interest classification. Cash/BS roll-forward identities do not independently validate the forecasts; additional financial lines are tracked, not scored.
  • Segment organic-growth diagnostics and company organic growth use different definitions. Historical rounded growth, unavailable comparators and several source/presentation labels remain imperfect.
  • Original financial assumptions and every scored EPS dependency are unchanged through the two repair rounds. Source capture limitations remain disclosed; no later target results were used.
Research sources